Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
| Status: | Completed |
|---|---|
| Conditions: | Depression, Major Depression Disorder (MDD) |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 10/14/2017 |
| Start Date: | May 2011 |
| End Date: | July 2012 |
Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
The purpose of this study is to determine whether GLYX-13 reduces depression score in
patients with treatment-resistant depression.
patients with treatment-resistant depression.
Inclusion Criteria:
- diagnosis of major depressive disorder consistent with DSM-IV-TR
- current episode greater than 8 weeks in duration
- Hamilton Depression score >/- 21
- less than 25% reduction in depression during current episode assessed by ATRQ
Exclusion Criteria:
- Axis diagnosis of other psychiatric disorders
- Experiencing hallucinations, delusions, other psychotic symptomatology
- ECT during current episode
We found this trial at
1
site
